In response to a new emergency contraception going S3, the PSA has updated its guidelines for pharmacists
Last week the AJP reported that EllaOne (ulipristal acetate 30mg tablets) had been rescheduled to a Pharmacist Only medicine as of 1 February.
EllaOne is an emergency contraception that became available in mid-2016, originally as prescription-only.
Prior to this, the levonorgestrel 1.5mg tablet was the only oral emergency contraption available in Australia.
Ulipristal is now approved for pharmacist supply as emergency contraception for up to 120 hours (five days) after unprotected intercourse.
In response to the news, the Pharmaceutical Society of Australia (PSA) has updated its Guidelines for the provision of emergency contraception and other resources, which can be accessed by PSA members.
Jan Ridd, PSA Executive Director Practice Support & Education, says the updated resources aim to support pharmacists and concisely describe the differences between the two emergency contraception options now available in Australia.
“These user-friendly resources include an updated guidance document for the provision of EC, which we recommend all pharmacists should familiarise themselves with to help with patient care,” says Ms Ridd.
“As the peak body for all pharmacists, PSA believes pharmacists need to be confident and ready to handle sensitive requests for EC from patients.
“The new PSA resources aim to guide pharmacists and assist their patients in making an informed decision about which EC is appropriate for their individual circumstances.”
An informative webinar by the PSA is also available and Australian pharmacists can register here.
The Guild Pharmacy Academy is also offering a CPD-accredited EllaOne online course.